Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.
Israel-based cellular therapy developer Gamida Cell has floated in a $50m initial public offering in which investors including pharmaceutical company Novartis bought $37.5m of the shares.
The company issued 6.25 million shares on the Nasdaq Global Market priced at $8.00 each, after originally setting a $13 to $15 range for 3.6 million shares earlier this month, giving it a market capitalisation of approximately $200m.
Novartis and Clal Biotechnology Industries (CBI), a subsidiary of conglomerate Access Industries, were both among…
